Günter Niegisch

[Günter Niegisch @GNiegisch]

Congrats to Andreas and Yue for the best paper award! #eau24 https://t.co/ngQmnTG26a

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @US_FDA alert: FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma! Via @ASCO @US_FDA alert !

Trial presented @myESMO #ESMO23 and published @NEJM

@OncoAlert @MattGalsky @sonpavde @MichvdHeijden

[Laura Bukavina @LauraBukavinaMD]

No matter how you splice it , analyze it or criticize it .. this is hope .. something we have not been able to say in a very very long time for many of our #bladdercancer patients and I am here for it

[Günter Niegisch @GNiegisch]

@tompowles1 @NEJM Congrats to @tompowles1 and the whole EV-302 study team for this important work. Writing the editorial was an honor!

[Günter Niegisch @GNiegisch]

Online now! Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer | NEJM https://t.co/X9fIMpMrZi

[Günter Niegisch @GNiegisch]

Insightful case discussion with an outstanding panel at #emuc23 with ⁦@amerseburger⁩ ⁦@DrYukselUrun⁩ , Kerstin Junker, N.Sanmamed and H. Thoeny!

[channel✨💖 @harlee_luv008]

CheckMate 901 folks #ESMO23 @BladderCancerUS @TischCancer @sonpavde @MichvdHeijden @DrYukselUrun
https://t.co/Zd6wR6QK7s

[Toni Choueiri, MD @DrChoueiri]

#Goosebumps #EV302 #ESMO23

Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦@tompowles1⁩

EV+Pembro irrespective…..WOW! 🤩

[Markus Eckstein @Markuseckstein3]

🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by @tompowles1. 🙌🔬🎗️ @urotoday @OncoAlert @myESMO

[Axel S. Merseburger @amerseburger]

EV-302/Keynote-A39 game changer in mBCa
OS 31.5 mo vs 16.1 👏🏼
Standing ovations for @tompowles1
@OncoAlert @myESMO @Silke_Gillessen

[Jan Philipp Radtke @JPRadtke]

Latest Publication by our
Düsseldorf UroRad group
https://t.co/ARjgzLFOag

[Günter Niegisch @GNiegisch]

Great time with our visiting professor ⁦@JLVasquez82⁩ !

[Günter Niegisch @GNiegisch]

Online now: DARO safety data in comorbid patients!
Efficacy and safety outcomes of darolutamide in patients with non-meta... https://t.co/PL7ZaCajRa

[Günter Niegisch @GNiegisch]

It’s published!

[European Association of Urology (EAU) @Uroweb]

🆕 Do not perform immediate cytoreductive nephrectomy in intermediate-risk patients who have an asymptomatic synchronous primary tumour and require systemic therapy.

#RenalCellCarcinoma #EAUguidelines

https://t.co/WQZngHa7Z9

[Tom Powles @tompowles1]

The addition of Talazoparib(PARPi) to enza in CRPC has most effect in BRCA+ve tumors. Effects in the remaining HRR population are marginal or -ve (e.g. ATM). This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ASCO2023

[Günter Niegisch @GNiegisch]

@AlisonBirtle @shilpaonc @AmerUrological @PGrivasMDPhD @MaxKates @UroDocAsh @UrogerliMD @ValGraj @drtanws Agree!

[Günter Niegisch @GNiegisch]

@shilpaonc @AndreaNecchi @AmerUrological @PGrivasMDPhD @MaxKates @UroDocAsh @UrogerliMD @ValGraj @drtanws Surgery (if fit) followed by maintenance. Local treatment may have an impact upon systemic treatment only (https://t.co/qWXxkMX6jV, though this was CTx w/o maintenance).

[Günter Niegisch @GNiegisch]

@SpreuThomas @Mohamedendourol @drkemalsarica @sbinhamrii @JnsHerrmann @joanfundi Perineal drainage, suprapubic catheter and IV antibiotics. Then reasses by CT scan/MRI when infection is controlled.

[Günter Niegisch @GNiegisch]

@shilpaonc @gavinthomas2015 Agree!